Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report

Mihaela Aldea; Rakiba Belkhir; Emeline Colomba; Pierre Blanchard; Francois-Xavier Danlos; Angela Botticella; Mario Terlizzi; Eric Deutsch; Cecile Le Péchoux; David Planchard; Jean-Marie Michot; Benjamin Besse; Antonin Levy

doi:10.3389/fimmu.2022.920130

Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report

Front Immunol. 2022 Oct 24:13:920130. doi: 10.3389/fimmu.2022.920130. eCollection 2022.

Authors

Affiliations

¹ Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France.
² Rheumatology, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Le Kremlin-Bicêtre, France.
³ Department of Radiation Oncology, International Center for Thoracic Cancers (CICT), Université Paris-Saclay, Gustave Roussy, Villejuif, France.
⁴ INSERM U1030, Molecular Radiotherapy, Université Paris-Saclay, Villejuif, France.
⁵ DITEP (Département des Innovations Thérapeutiques et Essais Précoces), Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Abstract

Radiotherapy can trigger immune-related out-of-field "abscopal" response. We report a patient with advanced NSCLC (non-small cell lung cancer) receiving long-term anti-PD1 (programmed cell death protein 1) who have developed out-of-field immune-related arthritis following pelvic irradiation.

Keywords: adverse (side) effects; anti-PD(L)1; immunoradiotherapy; immunotherapy; radiation therapy; toxicity.

Publication types

Case Reports

MeSH terms

Arthritis*
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / radiotherapy
Humans
Immune Checkpoint Inhibitors / adverse effects
Lung Neoplasms*

Substances

Immune Checkpoint Inhibitors